News

FDA advisers support pediatric studies of three investigational oncology agents

Publish date: December 12, 2014

 

AT AN FDA ADVISORY COMMITTEE MEETING

References

FDA panelists were cleared of potential conflicts.

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

Blood test charges vary widely among California hospitals
MDedge Hematology and Oncology
FDA advisers want more data on sunscreen safety
MDedge Hematology and Oncology
NHLBI expert panel issues guideline on sickle cell disease
MDedge Hematology and Oncology
Inflammatory rheumatic diseases raise venous thromboembolism risk
MDedge Hematology and Oncology
Dabigatran raises major bleeding risk
MDedge Hematology and Oncology
Extended use of oral anticoagulants reduces VTE recurrence
MDedge Hematology and Oncology
Sickle cell anemia trial halted because of early success
MDedge Hematology and Oncology
FDA expands ruxolitinib approval to include polycythemia vera
MDedge Hematology and Oncology
Young adults with ALL have better survival with pediatric regimens
MDedge Hematology and Oncology
Cancer patients with incidental VTE have high risk of recurrent thrombi
MDedge Hematology and Oncology